OpenExO Partners With Nectome, Buys Brain Preservation For Ill Patients

The following post was written and/or published as a collaboration between Benzinga’s in-house sponsored content team and a financial partner of Benzinga.

OpenExO, a decentralized ecosystem and global transformation platform, has announced that it has entered into a partnership with Nectome. 
 
The partnership agreement foresees collaboration between the OpenExO ecosystem and Nectome, leveraging the capabilities of decentralized storage systems and the underlying monetization mechanisms for use by the Nectome project – a research company dedicated to advancing the science of memory.

The company designs and conducts experiments to discover how the brain physically creates memories, advancing existing biological preservation techniques to better preserve the physical traces of human memory. Nectome is engaged in promoting the idea of ​​preserving human brains and then transferring consciousness to digital carriers. MIT Review calls such a technology a “high-tech embalming process.”
 
The technology is based on “vitrification”, also known as an aldehyde-stabilized cryopreservation process. In simple terms, the company offers to freeze the brains of willing clients with the ability to recreate a digital copy of them in the future.
 
Salim Ismail, the founder of Exo Economy, Silicon Valley veteran serial entrepreneur, announced the partnership with Nectome at a conference in Dubai, stating that OpenExO’s Exponential Growth solutions will be applied for Nectome.
 
“Nectome is an exponential and far-out meditech technology, so at OpenExo, our community of 8 thousand and growing leans into the most emergent technologies currently out there that are also addressing the most difficult topics, death for example,” as Salim Ismail noted on the partnership.
 
The use of the OpenExO ecosystem can assist in the development of Nectome’s storage and financial mechanisms through the use of the native platform EXOS tokens. The OpenExO Treasury will be using EXOS to pre-purchase the preservation of 5 full-body and brain end-of-life deanimations for terminally ill patients.
 
Ismail has also stated that the partnership aims to demonstrate the availability of such advanced medical technologies and to publicly display the informational accuracy it can deliver.
 
“We’ll have much, much more to say on this and related partnerships in the next few weeks on this topic. Yet, it’s just one example of how we are working to transform the future in a society that will cater to the freedom of choice and leverage decentralized systems of governance and technology,” as Salim Ismail concluded.
 
OpenExO is a Global Transformation Ecosystem helping organizations, institutions and people to transform and unlock abundance. OpenExO founder Salim Ismail is the Founding Executive Director of Singularity University and lead author of Exponential Organizations. He has been building disruptive digital companies as a serial entrepreneur since the early 2000s and is the author of “Exponential Organizations”. 

The ecosystem is also headed by co-founder Kent Langley – a leader and technology visionary with a deep technology background in Technology Operations, Cloud Computing, AI, Exponential Organizations, Data Science, and Blockchain. He is also a coach for organizations, leading them to powerful real-world results through the use of advanced technologies.
 
OpenExO, Inc. has been driving the development of global marketplaces through methodology and ecosystem development, with a 7,500 strong network of ExO Consultants, Advisors, Disruptors and Coaches delivering transformational work through partner and sister organizations, such as ExOWorks.

Image by StockSnap from Pixabay

The preceding post was written and/or published as a collaboration between Benzinga’s in-house sponsored content team and a financial partner of Benzinga. Although the piece is not and should not be construed as editorial content, the sponsored content team works to ensure that any and all information contained within is true and accurate to the best of their knowledge and research. This content is for informational purposes only and not intended to be investing advice.